Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSETTA RCC-208: Pumitamig in Advanced Renal Cell Carcinoma
NCT07293351Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2026
- Primary completion
- Nov 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 20
01
Overview
A Phase 2 trial of pumitamig in renal cell carcinoma (RCC), sponsored by Bristol Myers Squibb. Started Mar 2026; status: recruiting.
02
Drugs
pumitamig
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07293351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07293351.